Home › Multiple Myeloma › NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria:
* Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
* Participants who have provided informed consent for this study
About the study
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
What is being tested
Sponsor: Janssen Research & Development, LLC · Participants: 295 · Started: Mar 9, 2022
Contact the study team
Official record on ClinicalTrials.gov — NCT05201781
Locations in the U.S.
| Arizona | Mayo Clinic Cancer Center-Scottsdale, Phoenix |
| California | City of Hope, Duarte
University of California San Francisco, San Francisco
Stanford University Medical Center, Stanford |
| Florida | Moffitt Cancer Center, Tampa |
| Georgia | Emory University, Atlanta |
| Illinois | Northwestern University, Chicago
University of Chicago, Chicago |
| Indiana | Indiana University, Indianapolis |
| Kansas | Kansas University Medical Center, Westwood |
| Massachusetts | Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston |
| Michigan | Barbara Ann Karmanos Cancer Institute, Detroit |
| Minnesota | Mayo Clinic Rochester, Rochester |
| Missouri | Washington University School Of Medicine, St Louis |
| New Jersey | Hackensack University Medical Center, Hackensack
Rutgers Cancer Institute of New Jersey, New Brunswick |
| New York | Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Cancer Center, New York
Mount Sinai Medical Center, New York
Montefiore Medical Center, The Bronx |
| North Carolina | Levine Cancer Institute, Charlotte |
| Pennsylvania | University of Pennsylvania, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh |
| Tennessee | Sarah Cannon Research Institute, Nashville |
| Texas | MD Anderson Cancer Center, Houston |
| Wisconsin | Froedtert Memorial, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.